Financial services regulation trackers

This subtopic contains EU financial services regulation trackers:

  1. Checklist: Alternative Investment Fund Managers Directive (AIFMD)—timeline shows the implementation of AIFMD since 2009

  2. Checklist Bank Recovery and Resolution Directive (BRRD)—timeline shows the developments and implementation history of the EU BRRD

  3. Checklist Benchmarks Regulation—timeline outlines the key developments in relation to the EU Benchmarks Regulation

  4. Checklist Capital Requirements Directive IV (CRD IV) and Capital Requirements Regulation (CRR)—timeline outlines the key developments relating to EU CRD IV and the EU CRR. The EU’s package of prudential measures, the Capital Requirements Directive IV (Directive 2013/36/EU) (EU CRD IV) and the Capital Requirements Regulation (EU) 575/2013 (EU CRR) (also known collectively as EU CRD IV), implemented the global capital adequacy framework, Basel III, in the EU. Most of its provisions became effective on 1 January 2014, except for certain provisions specified in Article 521 of the EU CRR. As EU CRD IV combined a directive and a regulation, elements of the requirements were directly applicable in EU Member States and others required national implementation

  5. Checklist Central Securities Depositories Regulation (CSDR)—timeline outlines the

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

Commission publishes updated clinical trials guidance package

The European Commission's Directorate-General for Health and Food Safety has published a comprehensive package of updated clinical trials guidance documents, all endorsed by the Clinical Trials Coordination and Advisory Group (CTAG) on 15 October 2025. The package includes new recommendations on criteria for selecting a reporting Member State under Article 85(2)(c) of the Clinical Trials Regulation, establishing a workshare criterion when proposed reporting Member States decline the role, which occurs in approximately 30% of applications. The Commission has updated its recommendation paper on decentralised elements in clinical trials (Version 02), superseding the December 2022 version, with revised national provision overviews and guidance on informed consent, investigational medicinal product delivery, and remote monitoring. A new recommendation paper addresses frequent issues identified during Part I and Part II assessments, based on feedback from national competent authorities and ethics committees, covering investigational medicinal product dossiers, protocols, and safety reporting. The package also includes revised guidance on auxiliary medicinal products, effective 1 December 2025 for new applications, featuring an updated classification system distinguishing between authorised, modified authorised, and unauthorised auxiliary medicinal products with corresponding application and safety reporting requirements.

View EU Law by content type :

Popular documents